Phase 1b Dose-Finding Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 in Patients With Advanced or Metastatic Cancer
Phase of Trial: Phase I
Latest Information Update: 16 Nov 2018
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Dostarlimab (Primary) ; Niraparib (Primary) ; Paclitaxel (Primary)
- Indications Cancer; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions
- Sponsors TESARO
- 02 Nov 2018 Planned number of patients changed from 102 to 168.
- 02 Nov 2018 Planned End Date changed from 1 Mar 2019 to 1 Mar 2020.
- 02 Nov 2018 Planned primary completion date changed from 1 Sep 2018 to 1 Oct 2019.